Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alx, Astrazeneca, Blueprint, Clene, Gilead, Immunogenx, Novartis, Passage, Plus, Roche, Sanofi, Viridian and Virios.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astrazeneca, Ceapro, Fortress, Ginkgo, Homology, Nanopharmaceutics, Pasithea, Synlogic, Teneotwo.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alpine Immune, Intron, Evotec, Proqr, Psilera, SAB, Starpharma, Tetra, Vir, Volitionrx, Zai Lab.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avenda, Bodyport, Bot Image, Cerevasc, Imspex Diagnostics, Medalliance, Neuroone.
Following the readout of a phase II trial evaluating its COVID-19 oral antiviral Pentarlandir (SNB-01), Taiwan’s Syneurx International Corp. said it expects to launch a phase III test of the candidate in the next few months.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akebia, Cognition, Dizal, H. Lundbeck, Kazia, Otsuka, Tarsus, United.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Genbody, Vieworks, Wision.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascletis, Astrazeneca, Biocryst, Immunabs, Janssen, Jubilant, Panbela, Syros, Vaxcyte, Xortx.